Hims & Hers HealthXSWX:HIMS 81 3-Year ROIIC % is 12.72 as of Dec. 2025, which is 51% above its 10-year median of 8.43. GuruFocus rates XSWX:HIMS with a GF Score™ of 81/100 and a GF Value™ of CHF32.30. The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Hims & Hers Health ranks better than 63.52% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hims & Hers Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 12.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hims & Hers Health's 3-Year ROIIC % or its related term are showing as below:
XSWX:HIMS's 3-Year ROIIC % is ranked better than 63.52% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs XSWX:HIMS: 12.72
Hims & Hers Health (XSWX:HIMS) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hims & Hers Health 3-Year ROIIC % Related Terms
Hims & Hers Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's 3-Year ROIIC % falls into.
Hims & Hers Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 105.613 (Dec. 2025) - -68.6626515 (Dec. 2022) )
/
( 1522.716 (Dec. 2025) - 152.876 (Dec. 2022) )
=
174.2756515
/
1369.84
=
12.72%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hims & Hers Health (XSWX:HIMS) has a 3-Year ROIIC % of 12.72 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hims & Hers Health and its competitors. This is 51% above median its historical median of 8.43. According to the industry distribution chart, Hims & Hers Health ranks #344 out of 943 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Hims & Hers Health's 3-Year ROIIC % too high?
Hims & Hers Health's current 3-Year ROIIC % of 12.72 is 51% above median its 10-year median of 8.43. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Hims & Hers Health's value of 12.72 is 240.1% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #344 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hims & Hers Health has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's 3-Year ROIIC % compare to ?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #344 out of 943 companies for 3-Year ROIIC %. This puts Hims & Hers Health in the upper half of its industry. The industry median 3-Year ROIIC % is 3.74. Hims & Hers Health's value of 12.72 is 240.1% above this benchmark. While the company's 10-year median is 8.43 vs. the industry median of 3.74, Hims & Hers Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current 3-Year ROIIC % of 12.72 is 240.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current 3-Year ROIIC % is 12.72, which is 51% above median its own 10-year median of 8.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Hims & Hers Health (XSWX:HIMS) has a current 3-Year ROIIC % of 12.72. The stock's GF Value™ is CHF32.30, compared to a current price of CHF29.90 — trading 7.4% below its estimated fair value. The current 3-Year ROIIC % is 12.72, which is 51% above median its 10-year median of 8.43 and 240.1% above the Drug Manufacturers industry median of 3.74. Hims & Hers Health's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hims & Hers Health (XSWX:HIMS), the current 3-Year ROIIC % is 12.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (XSWX:HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of CHF29.90 is trading 7.4% below its estimated GF Value™ of CHF32.30.
Key valuation signals for XSWX:HIMS:
3-Year ROIIC %: 12.72 (51% above median its 10-year median of 8.43)
GF Value™: CHF32.30 vs. price of CHF29.90 (7.4% below fair value)
Industry Position: 240.1% above the Drug Manufacturers median (#344 of 943)
No single metric tells the full story. See the XSWX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score
Get the complete analysis for XSWX:HIMS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:HIMS has been successfully added to your 
